Skip to main content

Table 2 Analyses for prognostic indicators of Overall Survival

From: Long-term oncologic outcomes of radiotherapy combined with maximal androgen blockade for localized, high-risk prostate cancer

Variable

Overall Survival

Univariate analysis

Multivariate analysis

P Value

HR

P Value

HR

Age at diagnosis (years)

 ≤70 vs >70

0.035

5.812

0.174

――

Gland volume (mL)

 ≤33 vs >33

0.006

3.816

0.042

1.192

MAB

 Continuous vs Intermittent

0.583

――

0.457

――

PPB

 yes vs no

0.007

3.016

<0.001

6.358

Clinical stage

 ≤ T2c vs ≥T3a

<0.001

4.557

0.011

2.183

Gleason score

 ≤7 vs ≥8

0.001

3.356

<0.001

7.142

PSA at diagnosis (ng/mL)

 ≤10 vs 10~20 vs ≥20

0.027

1.558

0.014

3.492

Memorial Sloan-Kettering risk classification

 2~3 IS vs 1 HS vs 2 HS

<0.001

7.658

<0.001

5.479

PSA nadir (ng/mL)

 ≤1 vs >1

<0.001

9.473

0.012

4.553

Time to PSA nadir (months)

 ≤3 vs >3

0.012

3.113

0.038

1.249

PSA doubling time (months)

 ≤12 vs >12

0.042

2.665

0.028

5.511

PSA decrease (%)

 <90 vs ≥90

<0.001

13.463

<0.001

7.845

  1. MAB Maximal Androgen Blockade; PPB Permanent Prostate Brachytherapy; IS intermediate-Risk Standard; HS High-Risk Standard